Know Cancer

forgot password

Testing of Computer Aided Detection Software for Riverain Medical Group

Not Enrolling
Lung Cancer

Thank you

Trial Information

Testing of Computer Aided Detection Software for Riverain Medical Group

In 2000, data was presented to the FDA to demonstrate that a new system for computer
analysis could assist radiologists in the detection of small lung cancers on chest
radiographs. Radiologists using the system showed a statistically significant improvement in
lung cancer detection rate when they used the system, compared to their interpretation of
chest radiographs when they did not use the computer system. This study, along with other
supporting data, resulted in the FDA giving Pre-Market Approval for the system.

The system has undergone several improvements in software and hardware, and it is now
intended to test two different software systems to determine whether radiologists using the
systems can improve their detection of lung cancer on chest radiographs.

One of these systems processes the chest radiograph to decrease the emphasis given to the
shadow of the ribs and thereby enhances the ability of radiologists to detect disease in the
lungs. The second system performs a series of evaluations on chest radiographs and, based on
a complex system of analysis, points to locations on the chest radiograph that contain
solitary pulmonary nodules having the characteristics of primary lung cancer or solitary
metastases of cancer to the lungs.

This will be a test of radiologists to determine the degree of improvement, if any, that
results when they interpret chest radiographs that may or may not have cancer, first
interpreted without the computer and, second, with the images output by the software.

Inclusion Criteria:

- US American Board of Radiology Certified Radiologists in active clinical practice

Exclusion Criteria:

- Specialists in pulmonary or chest or cardio-pulmonary radiology Prior membership on
expert panels for this study who prepared cases Current or recent colleagues or
trainees (within 10 years) of the Principal Investigator

Type of Study:


Study Design:


Outcome Measure:

Improvement in cancer detection as measured by ROC methodology

Outcome Time Frame:

Three days of experiment over 3-5 months

Safety Issue:


Principal Investigator

Matthew T. Freedman, MD, MBA

Investigator Role:

Principal Investigator

Investigator Affiliation:

Georgetown University


United States: Institutional Review Board

Study ID:

Riverain SV 2.0.1 and OG5.0



Start Date:

May 2009

Completion Date:

June 2010

Related Keywords:

  • Lung Cancer
  • Lung Cancer
  • Chest Radiograph
  • Computer-aided Detection
  • Image processing
  • Lung Neoplasms



ISIS Imaging Science Research Center, Georgetown University Washington, District of Columbia  20057